Sign In  |  Register  |  About Sunnyvale  |  Contact Us

Sunnyvale, CA
September 01, 2020 10:10am
7-Day Forecast | Traffic

  • Search Hotels in Sunnyvale

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Clovis Oncology Inc (NQ: CLVS )

N/A UNCHANGED
Last Price Updated: 4:00 PM EST, Dec 20, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Clovis Oncology Inc

< Previous 1 2 3 4 5 6 7 Next >
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers Rail Vision Ltd. (NASDAQ: RVSN) shares jumped 51.7% to $2.0180 after gaining around 5% on Tuesday. Sharps Technology, Inc. (NASDAQ: STSS) rose 31.4% to $1.6815 after... 
Via Benzinga
Clovis Oncology: Q1 Earnings Insights
Clovis Oncology (NASDAQ:CLVS) reported its Q1 earnings results on Wednesday, May 4, 2022 at 08:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Clovis Oncology Announces First Quarter 2022 Operating Results and Provides Update on Clinical Development Programs
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology's Rubraca Significantly Improves PFS In Ovarian Cancer Regardless Of Biomarker Status
Via Benzinga
HER2-Targeted Therapies Introduced Early in Breast Cancer Treatment Offering Hope for Patients
Palm Beach, FL – May 4, 2022 – FinancialNewsMedia.com News Commentary – Globally, the R&D on breast cancer in all its forms has been steadily growing at a significant pace over the last several years... 
Via FinancialNewsMedia
Exposures COVID-19
Clovis Oncology Highlights Rubraca® (Rucaparib) and FAP-2286 Data to be Presented at 2022 ASCO Annual Meeting
From Clovis Oncology, Inc.
Via Business Wire
Advanced Immunological and Clinical Trials for Treating Ovarian Cancer Accelerating
Palm Beach, FL – April 25, 2022 – FinancialNewsMedia.com News Commentary – The formation of mutational cells or tissues in female reproductive organs called ovaries leads to ovarian cancer. Cancer... 
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Clovis Oncology Q1 2022 Earnings Conference Call On May 4, 2022 At 08:30 AM ET
Clovis Oncology (NASDAQ:CLVS) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. How to Attend Clovis Oncology (CLVS) Conference Call Follow this link to... 
Via Benzinga
Clovis Oncology to Announce First Quarter 2022 Financial Results and Host Webcast Conference Call on May 4
From Clovis Oncology, Inc.
Via Business Wire
Advancements of CAR-T Cell Therapies Importance Grows While Cancer Cases Increasing
Palm Beach, FL – April 14, 2022 – FinancialNewsMedia.com News Commentary – CAR-T therapy is a sort of treatment in which a patient’s T cells which is a type of immune system cell, are genetically... 
Via FinancialNewsMedia
Clovis Oncology Targeted Cancer Radiation Therapy Shows Greater Tumor Inhibition
Clovis Oncology Inc (NASDAQ: CLVS) announced two abstracts featuring  
Via Benzinga
Clovis Oncology Highlights Presentations on FAP-2286 and Rubraca® (Rucaparib) at the AACR Annual Meeting 2022
From Clovis Oncology, Inc.
Via Business Wire
68 Biggest Movers From Yesterday
Gainers GBS Inc. (NASDAQ: GBS) jumped 68% to settle at $1.31 on Monday. Zacks Small-Cap Research issued a note on GBS with an $8 valuation. Aterian, Inc. (NASDAQ: ATER) shares... 
Via Benzinga
35 Stocks Moving In Monday's Mid-Day Session
Gainers Aterian, Inc. (NASDAQ: ATER) shares jumped 43.5% to $3.3457. Aterian said Cynthia Williams has joined the Company's Board of Directors. Jumia Technologies AG (... 
Via Benzinga
55 Biggest Movers From Friday
Gainers Takung Art Co., Ltd. (NASDAQ: TKAT) surged 61.8% to close at $3.64 on Friday. Chicken Soup for the Soul Entertainment, Inc. (NASDAQ: CSSE) rose 43.8% to settle at $11.49... 
Via Benzinga
The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight
Biopharma stocks outperformed the broader market in the week ending April 2, thereby recouping the losses from the previous week. Clinical readouts and FDA decisions were among the chief catalysts that... 
Via Benzinga
53 Biggest Movers From Yesterday
Gainers Longeveron Inc. (NASDAQ: LGVN) shares jumped 105.4% to close at $13.80 on Thursday after the company announced the publication of results from a Phase 1 trial testing... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Longeveron (NASDAQ:LGVN) stock rose 60.6% to $10.79 during Thursday's regular session. As of 13:31 EST, this security is trading at a volume of 84.1 million... 
Via Benzinga
AMD Stock Downgrade: Why Barclay’s Thinks the Chip Company Is Headed Lower
Advanced Micro Devices (AMD) stock is slipping on Thursday as investors react to a downgrade from Barclays analyst Blayne Curtis. 
Via InvestorPlace
Clovis Oncology News: Why CLVS Stock Is Roaring Higher Today
Clovis Oncology (CLVS) stock is in the news Thursday as shares rocket higher thanks to positive data from a recent clinical trial. 
Via InvestorPlace
Why Clovis Oncology Stock Is Soaring Today
Clovis Oncology Inc (NASDAQ: CLVS) is trading higher Thursday morning after the company announced data from the monotherapy arm of the ATHENA trial achieved the primary... 
Via Benzinga
The Daily Biotech Pulse: Amylyx Announces Negative Adcom Vote, Clovis Jumps On Ovarian Cancer Data, Masimo Warns Of Q1 Shortfall
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Rise and shine, trader! We're getting ready for another busy day of trading with the biggest pre-market stock movers for Thursday! 
Via InvestorPlace
Clovis Oncology’s Rubraca® (Rucaparib) Significantly Improves Progression-Free Survival in First-line Maintenance Treatment in Women with Ovarian Cancer Regardless of Their Biomarker Status in Phase 3 ATHENA-MONO Trial
From Clovis Oncology, Inc.
Via Business Wire
Clovis Oncology and Evergreen Theragnostics Initiate Development and Manufacturing Services Agreement for Actinium-225-Labeled FAP-2286
From Clovis Oncology, Inc.
Via Business Wire
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers Surgalign Holdings (NASDAQ:SRGA) ... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
On Wednesday, 90 companies set new 52-week lows. Areas of Significance In Today's 52-Week Lows: The company with the largest market cap to set a new 52-week low was... 
Via Benzinga
Clovis Oncology Highlights Ongoing Phase 1/2 LuMIERE Clinical Study and Multi-Tumor Imaging Investigator-Initiated Trial of FAP-2286 Fibroblast Activation Protein-Targeted Radiotherapy Candidate at an Upcoming Nuclear Medicine Meeting
From Clovis Oncology, Inc.
Via Business Wire
88 Biggest Movers From Yesterday
Gainers Cyren Ltd. (NASDAQ: CYRN) shares surged 118.9% to settle at $4.75 on Thursday. Cyren recently announced a $12 million private placement. Indonesia Energy Corporation... 
Via Benzinga
Clovis Oncology Announces 2021 Operating Results and Anticipated 2022 Development Milestones
From Clovis Oncology, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Sunnyvale.com & California Media Partners, LLC. All rights reserved.